Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360770 | 0.73 | MAPT (0.41) | ALOX5KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL362165 | 0.72 | ADORA3 (0.50) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL3711518 | 0.68 | L3MBTL1 (0.52) | ALOX5KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL2964886 | 0.68 | NPC1 (0.47) | KDM4EALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL2978903 | 0.68 | MAPT (0.42) | ADORA2AALOX5KDM4EALDH1A1MAPT | |
| SCHEMBL2979080 | 0.67 | MAPT (0.48) | ALOX5KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL868954 | 0.67 | KDM4E (0.49) | KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL2970170 | 0.66 | PTGS1 (0.36) | KDM4EALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL2964669 | 0.66 | KDM4E (0.49) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL12920756 | 0.64 | ADORA3 (0.48) | ADORA3ADORA2AADORA1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-20140343089-A1 | NOREPINEPHRINE AND SELECTIVE SEROTONIN RECEPTOR BLOCKER AND USE THEREOF | HARBIN PHARMACEUTICAL CO., LTD. (CN) | 2014-11-20 | — | — | US | disclosed |
| US-20130184273-A1 | BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-2593458-A1 | BICYCLIC PYRIMIDINES | Bayer Intellectual Property GmbH (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007416-A1 | BICYCLIC PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-19 | — | — | WO | disclosed |
| EP-2396330-A1 | FUSED PYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184273-A1 | BICYCLIC PYRIMIDINES | PIK3CA, TYMS, PIK3CD | ADORA3 772/4885ADORA2A 586/4885ADORA1 733/4885 |
| US-20140343089-A1 | NOREPINEPHRINE AND SELECTIVE SEROTONIN RECEPTOR BLOCKER AND USE THEREOF | ADRB1, ADRA2B, ADRB3 | ADORA3 129/4885ADORA2A 179/4885ADORA1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.